DaVita Inc. logo

DaVita Inc. (DVA)

Market Closed
24 Feb, 20:00
NYSE NYSE
$
150. 91
-0.37
-0.24%
$
10.08B Market Cap
16.41 P/E Ratio
- Div Yield
590,738 Volume
7.83 Eps
$ 151.28
Previous Close
Day Range
146.67 151.39
Year Range
101 157.12
Want to track DVA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
DVA earnings report is expected in 75 days (11 May 2026)
Here's why Warren Buffett dumped $31 million worth of this stock

Here's why Warren Buffett dumped $31 million worth of this stock

Warren Buffett, the ‘Oracle of Omaha', managed to attain a roughly $142 billion net worth by consistently outperforming the markets. The Berkshire Hathaway (NYSE: BRK.B) chief executive officer (CEO) and chairman did so by utilizing a careful, level-headed approach to investing.

Finbold | 1 year ago
Warren Buffett's Berkshire Hathaway sells some DaVita; Shares fall on disappointing guidance

Warren Buffett's Berkshire Hathaway sells some DaVita; Shares fall on disappointing guidance

DaVita shares tumbled after issuing a weak outlook amid rising care costs, while big investor Berkshire offloaded some shares in a pre-planned agreement.

Cnbc | 1 year ago
DaVita Inc. (DVA) Q4 2024 Earnings Call Transcript

DaVita Inc. (DVA) Q4 2024 Earnings Call Transcript

DaVita Inc. (NYSE:DVA ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Nic Eliason - Group VP, IR Javier Rodriguez - CEO Joel Ackerman - CFO Conference Call Participants Joanna Gajuk - Bank of America AJ Rice - UBS Pito Chickering - Deutsche Bank Justin Lake - Wolfe Research Andrew Mok - Barclays Ryan Langston - TD Cowen Operator Good evening. My name is Michelle, and I will be your conference facilitator today.

Seekingalpha | 1 year ago
Berkshire sells some DaVita shares, cuts stake to 45%

Berkshire sells some DaVita shares, cuts stake to 45%

Berkshire Hathaway said on Thursday night it sold 203,091 shares of DaVita , reducing its stake in the kidney dialysis services provider to about 35.89 million shares, a 45% stake worth nearly $6.4 billion.

Reuters | 1 year ago
DaVita HealthCare (DVA) Beats Q4 Earnings and Revenue Estimates

DaVita HealthCare (DVA) Beats Q4 Earnings and Revenue Estimates

DaVita HealthCare (DVA) came out with quarterly earnings of $2.24 per share, beating the Zacks Consensus Estimate of $2.21 per share. This compares to earnings of $1.87 per share a year ago.

Zacks | 1 year ago
DaVita forecasts 2025 profit below estimates, shares plummet

DaVita forecasts 2025 profit below estimates, shares plummet

Dialysis firm DaVita projected annual profit below estimates on Thursday due to rising patient care costs, sending its shares down 11% in after-hours trading.

Reuters | 1 year ago
DVA Q4 Estimates Unchanged Before Earnings: How to Play the Stock?

DVA Q4 Estimates Unchanged Before Earnings: How to Play the Stock?

Continued strength in RPT is likely to have boosted DaVita's top line in the fourth quarter despite supply challenges weighing on its performance.

Zacks | 1 year ago
DaVita HealthCare (DVA) Increases Yet Falls Behind Market: What Investors Need to Know

DaVita HealthCare (DVA) Increases Yet Falls Behind Market: What Investors Need to Know

The latest trading day saw DaVita HealthCare (DVA) settling at $177.35, representing a +0.16% change from its previous close.

Zacks | 1 year ago
4 Stocks Trading Near 52-Week High With Room to Rise Further

4 Stocks Trading Near 52-Week High With Room to Rise Further

Investors target stocks that have been on a bullish run lately. Stocks like ENS, DVA, REVG and PAA are seeing price strength and the momentum is likely to continue.

Zacks | 1 year ago
DaVita HealthCare (DVA) Ascends While Market Falls: Some Facts to Note

DaVita HealthCare (DVA) Ascends While Market Falls: Some Facts to Note

In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $173.77, denoting a +0.32% change from the preceding trading day.

Zacks | 1 year ago
DaVita HealthCare (DVA) Upgraded to Strong Buy: Here's Why

DaVita HealthCare (DVA) Upgraded to Strong Buy: Here's Why

DaVita HealthCare (DVA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 1 year ago
Sell Nvidia, Buy This Stock

Sell Nvidia, Buy This Stock

Big things happened this weekend.

Zacks | 1 year ago
Loading...
Load More